CBD shows some promise in lab studies for reducing inflammation linked to arthritis, but the clinical evidence in humans is disappointing so far. The best-designed trial to date, published in The Lancet Regional Health, found that oral CBD at 600 mg per day provided no more pain relief than a placebo for knee osteoarthritis. That doesn’t mean CBD is worthless for every person or every form of arthritis, but it does mean the hype has outpaced the science.
What the Best Clinical Trial Found
The strongest evidence comes from a randomized, double-blind, placebo-controlled trial of 86 people with painful knee osteoarthritis. Participants took either 600 mg of oral CBD daily or a placebo, both on top of their regular acetaminophen. After eight weeks, both groups saw nearly identical pain improvements on a standard joint-pain scale: a reduction of 2.5 points in the CBD group versus 2.4 in the placebo group. The difference was statistically meaningless.
What did differ was side effects. The CBD group experienced significantly more adverse events (56% of all reported events) compared to placebo (44%). Liver enzyme elevations were three times more common in the CBD group: 15 people versus 5 on placebo. The researchers concluded that their results “do not support the use of cannabidiol as an analgesic supplement” for knee osteoarthritis.
Topical CBD Tells a Different Story
While oral CBD fell flat in that trial, a smaller randomized controlled trial of topical CBD showed more encouraging results. Eighteen people with thumb joint arthritis applied either a CBD cream (6.2 mg/mL in shea butter) or plain shea butter twice daily for two weeks, then switched treatments after a washout period. Those using the CBD cream reported significant improvements in pain and hand function compared to the control, with no adverse events.
This is a small study, and it doesn’t prove topical CBD works broadly for arthritis. But it hints that applying CBD directly to a superficial joint may work differently than swallowing a capsule. One possible explanation: topical application delivers CBD to local tissue without relying on the gut and liver to process it first, which is where oral CBD loses most of its potency. The researchers themselves noted that current trial evidence “does not support the use of purified oral CBD in pain,” suggesting the delivery method matters.
How CBD Affects Inflammation
In the lab, CBD does appear to tamp down a key inflammatory pathway. A 2025 study in Frontiers in Immunology showed that a high-CBD extract reduced activity in what’s called the NF-κB signaling pathway, one of the body’s main switches for turning on inflammation. Specifically, the extract dialed down the activation of immune cells called neutrophils in a dose-dependent way, meaning higher concentrations produced a stronger effect.
This is relevant to rheumatoid arthritis in particular, where the immune system mistakenly attacks joint tissue. If CBD can quiet that overactive immune signaling, it could theoretically slow the inflammatory process. But lab results in immune cells don’t automatically translate to real-world relief in a human joint. The gap between “reduces inflammation in a dish” and “makes your knees hurt less” remains wide, and no human trial has yet confirmed CBD as a disease-modifying treatment for rheumatoid arthritis.
Full-Spectrum vs. Isolate
Many CBD products are marketed as “full-spectrum,” meaning they contain other compounds from the hemp plant alongside CBD. The idea is that these compounds work together synergistically, a concept called the entourage effect. Some early evidence suggests full-spectrum extracts may perform better than pure CBD isolate, but a 2023 review found little solid scientific support for the entourage effect. Compounds in cannabis can also work against each other, a nuance that marketing materials tend to skip. At this point, there’s no reliable way to know whether full-spectrum products offer a meaningful advantage for arthritis.
Side Effects and Drug Interactions
CBD is often described as “well-tolerated,” but that framing deserves some context. In the knee osteoarthritis trial, high-dose oral CBD caused more side effects than placebo, including notable liver enzyme changes. If you’re already taking medications that stress the liver, this matters.
Drug interactions are a real concern. Researchers at Penn State identified 57 medications whose blood levels can be dangerously altered by cannabinoids. For arthritis patients specifically, the interaction with warfarin (a common blood thinner) is potentially serious. CBD can also amplify the sedating effects of opioids, certain anti-anxiety medications, antihistamines, and alcohol, raising the risk of excessive drowsiness and falls. If you take metformin for diabetes or proton pump inhibitors for heartburn, CBD may increase the likelihood of diarrhea.
What the Arthritis Foundation Recommends
The Arthritis Foundation has taken a cautious but open stance. They acknowledge that CBD “may help with arthritis-related symptoms, such as pain, insomnia and anxiety,” but note there have been no rigorous clinical studies in arthritis patients to confirm this. Their practical guidance: never use CBD as a replacement for disease-modifying drugs that prevent permanent joint damage in inflammatory arthritis types like rheumatoid arthritis.
If you want to try CBD, the Foundation suggests starting with a low dose and increasing in small increments weekly. They also recommend buying from companies that provide third-party lab certificates for each batch, since the FDA does not regulate CBD products for purity or potency. No CBD product is FDA-approved for arthritis or any pain condition. The only FDA-approved CBD medication, Epidiolex, is prescribed for certain seizure disorders.
The Regulation Gap
The FDA has issued warning letters to companies marketing CBD products with unproven health claims, but enforcement has been limited. Without federal regulation, the CBD you buy online or at a store may contain more or less CBD than the label states, or it may contain contaminants. A product labeled “500 mg CBD” has no guarantee of accuracy unless independently verified. This makes it difficult to even replicate the conditions of a clinical trial at home, since you can’t be sure what you’re actually taking.
This unregulated landscape is one reason the clinical picture stays murky. Even if CBD does help some people with certain types of joint pain, the products available to consumers vary so widely that individual experiences are hard to interpret. Someone who feels relief might be responding to CBD, to other plant compounds in a full-spectrum product, or to the placebo effect, which was substantial in the Lancet trial.